Clinical Trial Detail

NCT ID NCT02872116
Title Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

gastroesophageal junction adenocarcinoma

stomach cancer

Therapies

Capecitabine + Oxaliplatin

Ipilimumab + Nivolumab

Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.